Market Place
Sourcing Support
Applied DNA Reports Q2 Fiscal Financial Results & Progress
13 Feb 2025 //
ACCESSWIRE
Applied DNA Urges Shareholders To Vote Before Feb 14 Meeting
11 Feb 2025 //
ACCESSWIRE
Applied DNA Completes Buildout of GMP Facility
10 Jan 2025 //
ACCESSWIRE
Applied DNA Reschedules Investor Update Call
08 Jan 2025 //
ACCESSWIRE
Applied DNA Customer Initiates Phase I CAR T-Cell Trial
18 Dec 2024 //
ACCESSWIRE
Applied DNA Announces Q4 2024 Results, Restructures to Prioritize
17 Dec 2024 //
ACCESSWIRE
Applied DNA to Report Q4 FY24 Results, Sets January Webcast
16 Dec 2024 //
ACCESSWIRE
Applied DNA Prices $6.5M Registered Offering & Private Placement
30 Oct 2024 //
ACCESSWIRE
Applied DNA To Participate In Maxim Healthcare Virtual Summit
15 Oct 2024 //
ACCESSWIRE
Applied DNA Regains Nasdaq Minimum Bid Price Compliance
18 Sep 2024 //
ACCESSWIRE
Applied DNA Receives Linea DNA Follow-On Order For Cancer Diagnostic Application
17 Sep 2024 //
ACCESSWIRE
Applied DNA To Showcase Linea IVT Platform For GMP RNA Manufacturing At Summit
17 Sep 2024 //
ACCESSWIRE
Applied DNA Launches Mpox Clade I and Clade II Testing Service
11 Sep 2024 //
ACCESSWIRE
Applied DNA Submits Validation For Expanded Mpox Virus Assay In New York
23 Aug 2024 //
ACCESSWIRE
Applied DNA To Expand Linea Mpox Assay For Clade I 2023
19 Aug 2024 //
ACCESSWIRE
Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results
08 Aug 2024 //
ACCESSWIRE
Applied DNA To Report Q3 Fiscal 2024 Results On August 8
07 Aug 2024 //
ACCESSWIRE
Applied DNA To Showcase Linea IVT At mRNA-Based Therapeutics Summit
29 Jul 2024 //
ACCESSWIRE
Applied DNA Signs CertainT Cotton Traceability Deal With Indus Group
25 Jul 2024 //
ACCESSWIRE
US Defense Logistics Agency Extends Applied DNA`s Counterfeit Contract
18 Jul 2024 //
ACCESSWIRE
Applied DNA Partners With GenXys To Deploy Clinical Decision Support PGx Testing
18 Jun 2024 //
ACCESSWIRE
SpendMend`s Trulla Optimizes Pharmacy Procurement At Froedtert Health
13 Jun 2024 //
ACCESSWIRE
Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results
10 May 2024 //
ACCESSWIRE
Applied DNA Enters into Agreement with Alphazyme
18 Mar 2024 //
ACCESSWIRE
Applied DNA Names Executive Director of Quality and cGMP Programs
07 Sep 2023 //
CONTRACT PHARMA
Applied DNA Files Patent Applications for Methods of Double-Stranded RNA Mitigation
23 Aug 2023 //
ACCESSWIRE
Applied DNA Reports Third Quarter Fiscal 2023 Financial Results
10 Aug 2023 //
ACCESSWIRE
Applied DNA Acquires RNA Polymerase Developer Spindle Biotech
13 Jul 2023 //
ACCESSWIRE
Applied DNA Achieves Milestone for Large-Scale linearDNA Production
29 Mar 2023 //
BUSINESSWIRE
Applied DNA Submits Validation Package for Approval of PGx
22 Mar 2023 //
BUSINESSWIRE
Applied DNA Announces New York State Award Valued at Up To $1.5 Million
10 Feb 2023 //
BUSINESSWIRE
Applied DNA Reports First Quarter Fiscal 2023 Financial Results
09 Feb 2023 //
BUSINESSWIRE
Applied DNA Announces Publication Validating Potential Use of linearDNA
05 Jan 2023 //
BUSINESSWIRE
Applied DNA to Establish First Enzymatic cGMP DNA Manufacturing Capacity
24 Oct 2022 //
BUSINESSWIRE
Applied DNA Announces Receipt of Largest Single Purchase Order for LinearDNA
10 Oct 2022 //
BUSINESSWIRE
Applied DNA’s Subsidiary Publishes that a LinearDNA Vaccine Candidate
30 Sep 2022 //
BUSINESSWIRE
Applied DNA to Present at the H.C. Wainwright Global Investment Conference
07 Sep 2022 //
BUSINESSWIRE
Applied DNA Launches Monkeypox Testing Service
06 Sep 2022 //
BUSINESSWIRE
Applied DNA Submits PCR-based Monkeypox Virus Diagnostic Test for Approval
19 Aug 2022 //
BUSINESSWIRE
Applied DNA Reports Third Quarter Fiscal 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
Applied DNA Biotherapeutics Subsidiary Reports LinearDNA™ Platform Development Milestone
10 Aug 2022 //
PRESS RELEASE
Applied DNA Announces Pricing of $12 Million Upsized Public Offering
04 Aug 2022 //
BUSINESSWIRE
Applied DNA Initiates Analytical Validation of PCR-based Diagnostic Test
02 Aug 2022 //
BUSINESSWIRE
LineaRx and EvviVax Publish Additional Proof-of-Concept Data on LinearDNA
25 Jul 2022 //
BUSINESSWIRE
LineaRx to Present Data on Advantages of its Enzymatically Produced LinearDNA
22 Jul 2022 //
BUSINESSWIRE
Applied DNA Launches Initiatives to Expand Awareness of LinearDNA Platform
29 Jun 2022 //
BUSINESSWIRE
Applied DNA to Participate in Fireside Chat at 34th ROTH Conference
10 Mar 2022 //
BUSINESSWIRE
Applied DNA Announces Closing of $4.2 Million Registered Direct Offering
24 Feb 2022 //
BUSINESSWIRE
Applied DNA Announces Pricing of $4.2 Million Registered Direct Offering
22 Feb 2022 //
BUSINESSWIRE
Applied DNA Q1 Fiscal 2022 Financial Results Feature Record Quarterly Revenues
10 Feb 2022 //
BUSINESSWIRE
Applied DNA to Deploy Linea 1.0 COVID-19 Assay for Rapid Detection of BA.2
28 Jan 2022 //
BUSINESSWIRE
Applied DNA Submits Request for EUA to FDA for Linea 2.0 COVID-19 Assay
21 Jan 2022 //
BUSINESSWIRE
Applied DNA Receives NYSDOH Conditional Approval for Linea 2.0 COVID-19 Assay
04 Jan 2022 //
BUSINESSWIRE
Applied DNA to introduce Linea 2.0 assay kit to address Omicron
29 Nov 2021 //
PHARMABIZ
Applied DNA, CLEARED4 Offer Fast, Cost-Effective and Turnkey Integrated Solution
05 Nov 2021 //
BUSINESSWIRE
Applied DNA Submits Request for EUA to FDA for Linea SARS-CoV-2 Mutation Panel
25 Oct 2021 //
BUSINESSWIRE
Applied DNA to Participate at H.C. Wainwright Global Investment Conference
07 Sep 2021 //
BUSINESSWIRE
Applied DNA Schedules Fiscal 2021 Third Quarter Financial Results
05 Aug 2021 //
BUSINESSWIRE
Applied DNA Awarded The City University of New York COVID-19 Testing Contract
04 Aug 2021 //
BUSINESSWIRE
Applied DNA Announces Data on its vaccine
07 Jun 2021 //
BUSINESSWIRE
